JavaScript is disabled for your browser. Some features of this site may not work without it.
Economic evaluation of Pembrolizumab combination therapy compared to standard of care chemotherapy as a first-line treatment for previously untreated, metastatic, non-squamous patients with metastatic non-small cell lung cancer (NSCLC)